Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Current Deferred Revenue (2016 - 2020)

Karyopharm Therapeutics (KPTI) has disclosed Current Deferred Revenue for 9 consecutive years, with $297000.0 as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Current Deferred Revenue fell 87.31% year-over-year to $297000.0, compared with a TTM value of $297000.0 through Dec 2020, down 87.31%, and an annual FY2020 reading of $297000.0, down 87.31% over the prior year.
  • Current Deferred Revenue was $297000.0 for Q4 2020 at Karyopharm Therapeutics, roughly flat from $297000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $19.7 million in Q1 2018 and bottomed at $263000.0 in Q1 2016.
  • Average Current Deferred Revenue over 5 years is $3.9 million, with a median of $1.0 million recorded in 2017.
  • The sharpest move saw Current Deferred Revenue surged 6798.25% in 2018, then crashed 88.75% in 2019.
  • Year by year, Current Deferred Revenue stood at $280000.0 in 2016, then rose by 8.21% to $303000.0 in 2017, then surged by 2989.77% to $9.4 million in 2018, then plummeted by 74.99% to $2.3 million in 2019, then tumbled by 87.31% to $297000.0 in 2020.
  • Business Quant data shows Current Deferred Revenue for KPTI at $297000.0 in Q4 2020, $297000.0 in Q2 2020, and $2.3 million in Q4 2019.